The offering is a large dilutive event but comes on the heels of strong clinical data and funds a deep pipeline through multiple Phase 3 readouts. Watch for near-term price pressure from the 6% discount and potential secondary selling. The Voyage GAD topline (early Q3) and Panorama GAD topline (late Q3) are the next major catalysts that could offset dilution if positive. The 60-day lock-up expiration in late August may add overhang.
Price Chart
Executive Summary
Definium Therapeutics priced a 20.6M share follow-on offering at $34.00/share, raising ~$659M net proceeds (~$758M if underwriters exercise the greenshoe in full). The offering represents ~19.8% dilution on pre-offering shares outstanding (104M) and was priced at a ~6% discount to the $36.18 close. Proceeds will fund R&D for DT120 (psychedelic-based GAD/MDD/PTSD candidate) and DT402 (ASD candidate), plus commercialization prep. The offering follows the highly positive June 22 Emerge Phase 3 MDD data (p<0.0001 on primary endpoint) and comes ahead of Voyage/Panorama GAD readouts expected in Q3 2026.
Key Facts
- 20,588,236 common shares offered at $34.00/share (6% discount to $36.18 close)
- Net proceeds ~$659M ($758M with full greenshoe of 3,088,235 additional shares)
- Pre-offering shares outstanding: 104,044,508; post-offering: 124,632,744 (19.8% dilution)
- Underwriters: J.P. Morgan, Jefferies, Leerink, BofA, Evercore, Stifel, Oppenheimer, LifeSci Capital
- 60-day lock-up on company and insiders
- Proceeds for R&D, DT120 commercialization prep, and working capital
- Recent positive Phase 3 Emerge MDD data (June 22, 2026) met primary endpoint (p<0.0001)
- Upcoming catalysts: Voyage GAD topline (early Q3 2026), Panorama GAD topline (late Q3 2026)
Financial Impact
~$659M net proceeds raised, representing ~19.8% dilution at a ~6% discount to market. Pre-offering net tangible book value was $2.49/share; post-offering adjusted to $7.37/share, implying $26.63/share dilution for new investors.
Risk Factors
- 19.8% immediate dilution to existing shareholders
- Potential for further dilution if greenshoe exercised in full (total 23.7M shares)
- Stock price may face pressure from the 6% offering discount and secondary market absorption
- Clinical risk: Voyage/Panorama GAD trials may not replicate Phase 2b success
- Pre-revenue biotech with no approved products; relies on successful clinical outcomes and regulatory approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-077349 |
| Document: tm2618395d2_ex-filingfees.htm | 0001104659-26-077349 |
| Document: 0001104659-26-077349-index-headers.html | 0001104659-26-077349 |
| Document: 0001104659-26-077349-index.html | 0001104659-26-077349 |
| Document: 0001104659-26-077349.txt | 0001104659-26-077349 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $40.25 $39.28 | ▼ −2.41% | ▼ −2.52% | $37.40 (−7.08%) |
Aug 12, 2026 7w ago | 8-K | $42.79 $45.82 | ▲ +7.08% | ▲ +7.53% | $37.40 (−12.60%) |
Aug 9, 2026 7w ago | Institutional Cluster | $45.15 $45.26 | ▲ +0.24% | ▲ +0.29% | $37.40 (−17.17%) |
Jun 25, 2026 14w ago | 144 | $44.95 $44.19 | ▼ −1.69% | ▼ −3.86% | $37.40 (−16.80%) |
Jun 25, 2026 14w ago | 144 | $44.95 $44.19 | ▼ −1.69% | ▼ −3.86% | $37.40 (−16.80%) |
Jun 24, 2026 14w ago | 8-K | $44.79 $43.40 | ▲ +3.10% | ▲ +4.66% | $37.40 (+16.50%) |
Jun 24, 2026 14w ago | 424B5 | $44.79 $43.40 | ▲ +3.10% | ▲ +4.66% | $37.40 (+16.50%) |
Jun 22, 2026 14w ago | 424B5 | $36.18 $46.55 | ▼ −28.66% | ▼ −27.65% | $37.40 (−3.37%) |
Apr 27, 2026 22w ago | DEFA14A | $21.27 $21.75 | ▲ +2.26% | ▲ +0.56% | $37.40 (+75.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access